Chifeng Addisun Pharmaceutical Co., Ltd. was established in September 2007 with a registered capital of 30 million yuan. At present, the company has hydroxyethyl starch 200/0.5 and hydroxyethyl starch 130/0.4 in the hydroxyethyl starch series. The number of the variety. The company has obtained the patent for this product in 2011. Patent name: A method for preparing hydroxyethyl starch, patent number: ZL 2008 1 0121106.1. The total construction area of ​​the first phase of the project is 10,000 square meters. The company's existing production level is in the leading position in the domestic industry, and has the international advanced technology level, the product quality has reached the European Pharmacopoeia EP7.0 standard, is the first company in Inner Mongolia to pass the 2010 version of GMP certification. In 2016, we invested in the construction of the second phase of the project. Based on the expansion of the high-value-added cephalosporin antibiotics, the project focused on the development of the last line of antibiotics, carbapenems (Pinan), and half of the international research and development. Targeting anti-tumor drug bulk drugs, and carrying the company's original innovative drug raw material drug industry base. Chifeng Addisun Pharmaceutical Phase II project newly built 4 synthetic raw material drug workshops (anti-tumor synthesis workshop, Peinan synthesis workshop, multi-functional synthesis workshop, cephalosporin synthesis workshop), public engineering building, 3 dangerous goods warehouses, 1 multifunctional comprehensive The warehouse was rebuilt with 10 buildings including multi-purpose complex building with a building area of ​​27,000 m2. The project has completed an investment of about 300 million yuan. After the project is completed, the annual output value of all workshops is estimated to be 363 million yuan, the expected economic benefit is 96 million yuan, the annual tax is 16.55 million yuan, the annual profit is 79.45 million yuan, and the investment profit and tax rate is 48.06%. . It is estimated that 2020 can produce 25 tons of cephalosporin raw materials, 10 tons of Peony raw materials and 10 tons of targeted anti-tumor drugs, with an annual output value of more than 360 million yuan, profits and taxes exceeding 100 million yuan, and 500 people for resettlement. After the completion of the project, it will not only improve the industrial structure of the raw materials in the park, but also ensure the current production capacity of the company's self-use raw materials, laying a solid foundation for the company's follow-up industry and product layout. It has become a model for domestic high-end API manufacturing bases.